NS5A inhibitors

2017-08-01T18:25:01+03:00[Europe/Moscow] en true Ledipasvir/sofosbuvir, Ledipasvir, Deleobuvir, Ombitasvir, Velpatasvir, Velpatasvir/sofosbuvir, Daclatasvir, Ravidasvir, Odalasvir, Sofosbuvir/daclatasvir, Samatasvir flashcards NS5A inhibitors
Click to flip
  • Ledipasvir/sofosbuvir
    Ledipasvir/sofosbuvir (trade name Harvoni) is a two-drug combination for the treatment of hepatitis C.
  • Ledipasvir
    Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.
  • Deleobuvir
    Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C.
  • Ombitasvir
    Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection.
  • Velpatasvir
    Velpatasvir is an inhibitor of NS5A used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes.
  • Velpatasvir/sofosbuvir
    Velpatasvir/sofosbuvir (trade name Epclusa) is a two-drug combination for the treatment of hepatitis C.
  • Daclatasvir
    Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV).
  • Ravidasvir
    Ravidasvir (PPI-668) is an investigational NS5A inhibitor in clinical trials for chronic hepatitis C genotype 4.
  • Odalasvir
    Odalasvir (INN, previously known as ACH-3102) is an investigational new drug in development for the treatment of hepatitis C.
  • Sofosbuvir/daclatasvir
    Daclatasvir/sofosbuvir (trade name Darvoni) is a two-drug combination for the treatment of hepatitis C.
  • Samatasvir
    Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C.